Unlock instant, AI-driven research and patent intelligence for your innovation.

Lipid formulated DSRNA targeting the PCSK9 gene

A lipid and gene expression technology, applied in the field of dsRNA composition, can solve the problems of lowering LDLc level, total cholesterol level and LDLc cholesterol level, etc.

Inactive Publication Date: 2015-02-11
ALNYLAM PHARMA INC
View PDF171 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In both cases, PCSK9 loss-of-function resulted in reduced total and LDLc cholesterol levels
A review of research results over the past 15 years found that deletion of one copy of PCSK9 reduces LDLc levels and leads to increased ability to combat cardiovascular disease risk (Cohen et al., 2006 N. Engl. J. Med., 354., 1264-1272)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipid formulated DSRNA targeting the PCSK9 gene
  • Lipid formulated DSRNA targeting the PCSK9 gene
  • Lipid formulated DSRNA targeting the PCSK9 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0408] The gene walking of embodiment 1.PCSK9 gene (gene walking)

[0409] siRNA design was performed for identification in two independent screens:

[0410] a) siRNA targeting human and mouse or rat PCSK9 mRNA, and

[0411] b) All reactive human siRNAs predicted to be specific for the target gene PCSK9.

[0412] The mRNA sequences of human, mouse and rat PCSK9 were used: the human sequence NM_174936.2 was used as a reference sequence throughout the siRNA selection process.

[0413] In the first step, a 19-mer extension was identified that is conserved in human and mouse and in the human and rat PCSK9 mRNA sequences, resulting in human-mouse cross-reactive siRNAs as well as human- and rat-cross-reactive siRNAs siRNA screening.

[0414] siRNAs specifically targeting human PCSK9 were identified in a second screen. All possible 19mer sequences of human PCSK9 were extracted and defined as candidate target sequences. Table 1a and Table 2a list all sequences that cross-react ...

Embodiment 2

[0432] Example 2. dsRNA synthesis

[0433] Reagent source

[0434] Where the source of a reagent is not explicitly indicated herein, the reagent can be obtained from any supplier of molecular biology reagents at a standard of quality / purity consistent with molecular biology applications.

[0435] siRNA synthesis

[0436] Using Expedite 8909 synthesizer (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany) and controlled pore glass (CPG, Proligo Biochemie GmbH, Hamburg, Germany) was used as a solid support to generate single-stranded RNA by solid-phase synthesis on a 1 μmolar scale. RNA and RNA containing 2'-O-methyl nucleotides were produced by solid phase synthesis using the corresponding phosphoramidites and 2'-O-methylphosphoramidites (Proligo Biochemie GmbH, Hamburg, Germany), respectively. These structures were synthesized using standard nucleoside phosphoramidite chemistry (e.g., as described by Current protocols in nucleic acid chemistry, Beaucage...

Embodiment 3

[0469] Example 3. PCSK9 in HuH7, HepG2, Hela and Monkey Primary Hepatocytes siRNA screening found highly active sequences

[0470] HuH-7 cells were obtained from JCRB Cell Bank (Japanese Collection of Research Bioresources) (Shinjuku, Japan, cat. No.: JCRB0403). at 37°C and 5% CO 2 In a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany) supplemented with 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany, cat.No.S0115), penicillin 100U / ml, Streptomycin 100 μg / ml (Biochrom AG, Berlin, Germany, cat.No.A2213) and Dulbecco's MEM medium (Biochrom AG, Berlin , Germany, cat.No.F0435) cultured cells. HepG2 cells and Hela cells were obtained from the American Type Culture Collection (Rockville, MD, cat.No.HB-8065), and cultured at 37°C and 5%CO2 In a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany) in an atmosphere supplemented with 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany, c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods using lipid formulated siRNAs targeting the PCSK9 gene.

Description

technical field [0001] The present invention relates to compositions comprising lipid-formulated dsRNA targeting the PCSK9 gene and methods of treating diseases caused by expression of the PCSK9 gene. [0002] Cross References to Related Applications [0003] This application claims U.S. Provisional Application No. 61 / 187,169, filed June 15, 2009, U.S. Provisional Application No. 61 / 218,350, filed June 18, 2009, U.S. Provisional Application No. 61 / 218,350, filed September 22, 2009 Application No. 61 / 244,790, U.S. Provisional Application No. 61 / 285,598 filed December 11, 2009, U.S. Provisional Application No. 61 / 293,474 filed January 8, 2010 and March 12, 2010 Priority to filed U.S. Provisional Application No. 61 / 313,578, the contents of all of which are hereby incorporated by reference in their entirety for all purposes. [0004] Sequence Listing Citation [0005] This application includes a sequence listing submitted electronically in the form of a text file named 16733...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/11A61K9/127
CPCA61K9/0019A61K9/1273A61K9/1272A61K31/713C12N15/1137A61K47/545A61K47/55A61K47/6911A61K38/1709A61P35/00A61P3/06A61P43/00A61P9/10A61K9/127A61K48/00A61K38/17A61K31/7105C12N2310/315C12N2310/321C12N2310/322C12N2310/3515
Inventor K·菲吉拉德G·辛克尔A·阿金克S·米尔斯泰恩
Owner ALNYLAM PHARMA INC